There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HTG Molecular Diagnostics (HTGM – Research Report) and Galera Therapeutics (GRTX – Research Report) with bullish sentiments.
HTG Molecular Diagnostics (HTGM)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics, with a price target of $3.00. The company’s shares closed last Wednesday at $0.99, close to its 52-week low of $0.46.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on HTG Molecular Diagnostics is a Moderate Buy with an average price target of $3.00.
Galera Therapeutics (GRTX)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Galera Therapeutics today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.32, close to its 52-week low of $1.15.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Galera Therapeutics with a $6.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HTGM: